Team:Virginia
iGEM 2015
Welcome the University of Virginia iGEM 2015 Wiki! Use the navigation bar at the top of every page to move between pages. Please let us know if you have any comments or questions about our project by visiting the “Contact Us” page.
(click to close)
University of Virginia iGEM 2015
Home
Team
Project
Policy and Practices
Attributions
Contact Us
House of Carbs
A Novel Solution to Minimizing Postprandial Hyperglycemic Spikes
Project Overview
The Problem: Diabetes Mellitus and Hyperglycemia
SHOW LESS
SHOW MORE
From diabetes mellitus a number of devastating complications, such as amputations, blindness, crippling neuropathies, and many others, can arise from increased blood sugar levels on a regular basis, but many of        the major complications of diabetes arise from drastic fluctuations in the blood glucose        level (Ceriello et al., 2012). Up to two-thirds of people with diabetes die of        cardiovascular disease (CVD) brought about by diabetes-related macrovascular diseases        (Deshpande et al. 2008). In fact, the risk for cardiovascular disease mortality is 2 to 4        times higher in people with diabetes than in people who do not have diabetes.        Additionally, diabetic retinopathy is the most common microvascular complication        among people with diabetes and results in more than 10,000 new cases of blindness per        year. Retinopathy is associated with prolonged hyperglycemia; it is slow to develop, and        there is some evidence that it can begin to develop as early as 7 years before clinical        diagnosis of diabetes (Deshpande et al., 2008).
Postprandial (post-meal) blood sugar spikes specifically are one of the most        damaging complications of diabetes (Parkin et al., 2002). Many diabetics are able to        effectively manage post-meal glycemic spikes with self-administered doses of insulin,        but these hyperglycemic incidents still kill more Americans per year than any other        diabetes-related complications (Parkin et al., 2002). Arguably, the gravest consequence of        glycemic spikes in diabetes patients is the development of progressive macrovascular        disease (MVD), which affects the large blood vessels of the body, hardening and        blocking these vessels (Ceriello et al., 2012). MVD is the leading cause of death among        T2DM patients in the United States, causing up to 65% of diabetes-related deaths, making it a huge target for diabetes treatments research (Deshpande et al., 2008). MVD        also frequently leads to other severe complications such as ischemia in the extremities        and blindness (Haffner et al., 1998).
Controlling Hyperglycemic Spikes
SHOW LESS
SHOW MORE
For many T1DM and T2DM patients, it has been shown that the regular        control and management of blood glucose levels prevents many of the vascular        complications of the disease, but most of the time control over glucose is difficult to        attain because the self-dosing insulin treatment system that a lot of moderately to        severely sick diabetes patients use is often hard to calibrate and use (Parkin et al., 2002).
Compared to sucrose-rich food, starch-rich food has been found to create less        fluctuation in blood glucose levels, and thus is beneficial to diabetes patients and        hyperglycemia patients. There is evidence that this flatter response caused by a starch       rich meal is associated with the slower rate of digestion of complex sugars versus simple        sugars (Jenkins, Wolever, & Jenkins, 1988). Thus, if some of the simple sugars are first        converted into complex saccharides inside the E. coli and then released back into small        intestine, a similar flatter glycemic response will take place, which will be beneficial to        the patients.
Our Devices
SHOW LESS
SHOW MORE
We have assembled one plasmid with genes that dictate a controllable level of simple sugars uptake and one plasmid to produce glucan and fructan from simple sugars and then lyse to release the complex sugars back into the environment. In essence, this microbial device runs on two genetic devices -- an uptake circuit and a polymerization circuit.
In order to learn more details, please visit the Project page.
Show References
Hide References
References
A. Ceriello, S. Colagiuri, (2011). Guideline for management of postmeal glucose in         diabetes. International Diabetes Federation Guideline Development Group,         http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf ,         Accessed May. 6th, 2015
American Diabetes Association (2014). National Diabetes Statistics Report.        http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf         Accessed May. 5th, 2015
Anal, A. K., & Singh, H. (2007). Recent advances in microencapsulation of probiotics for         industrial applications and targeted delivery. Trends in Food Science & Technology, 18(5), 240–251. http://doi.org/10.1016/j.tifs.2007.01.004
Anan, F., Masaki, T., Eto, T., Fukunaga, N., Iwao, T., Kaneda, K., ... Yoshimatsu, H.         (2008). Postchallenge Plasma Glucose and Glycemic Spikes Are Associated with         Pulse Pressure in Patients with Impaired Glucose Tolerance and Essential         Hypertension. Hypertension Research, 31(8), 1565–1571.         http://doi.org/10.1291/hypres.31.1565
AHFS Consumer Medication Information [Internet]. Bethesda (MD): American Society         of Health-System Pharmacists, Inc.; ©2008. Acarbose; [revised 2015 Feb. 15;         reviewed 2015 Apr. 28; cited 2015 May. 3]; Available from:         http://www.nlm.nih.gov/medlineplus/druginfo/meds/ a696015.html
AHFS Consumer Medication Information [Internet]. Bethesda (MD): American Society         of Health-System Pharmacists, Inc.; ©2008. Pramlintide; [revised 2015 Feb. 15;         reviewed 2015 Apr. 28; cited 2015 May. 3]; Available from:        http://www.nlm.nih.gov/medlineplus/druginfo/meds/a605031.html
Banguela, A., Arrieta, J. G., Rodríguez, R., Trujillo, L. E., Menéndez, C., & Hernández,         L. (2011). High levan accumulation in transgenic tobacco plants expressing the         Gluconacetobacter diazotrophicus levansucrase gene. Journal of Biotechnology,         154(1), 93–98. http://doi.org/10.1016/j.jbiotec.2011.04.007
Barr EL, Zimmet PZ, Welborn TA et al. (2007). "Risk of cardiovascular and all-cause         mortality in individuals with diabetes mellitus, impaired fasting glucose, and         impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study         (AusDiab)". Circulation 116 (2): 151–7.
Bernard, A. M., Anderson, L., Cook, C. B., & Phillips, L. S. (1999). What do internal         medicine residents need to enhance their diabetes care? Diabetes Care, 22(5),         661–666. http://doi.org/10.2337/diacare.22.5.661
Boada C, Martínez-Moreno J. Pathophysiology of diabetes mellitus type 2: beyond the         duo "insulin resistance-secretion deficit.". Nutricion Hospitalaria [serial online].         March 2, 2013;28:78-87. Available from: Fuente Académica, Ipswich, MA.         Accessed April 16, 2015.
B. Göke, H. F. (1995). Voglibose (AO128) Is an Efficient α-Glucosidase Inhibitor and         Mobilizes the Endogenous GLP-1 Reserve. Digestion, 56(6), 493–501.         http://doi.org/10.1159/000201282
Brown, J. B., Harris, S. B., Webster-Bogaert, S., Wetmore, S., Faulds, C., & Stewart, M.         (2002). The role of patient, physician and systemic factors in the management of         type 2 diabetes mellitus. Family Practice, 19(4), 344–349.         http://doi.org/10.1093/fampra/19.4.344
Butterworth, P. J., Warren, F. J., & Ellis, P. R. (2011). Human α-amylase and starch         digestion: An interesting marriage. Starch - Stärke, 63(7), 395–405.         http://doi.org/10.1002/star.201000150
Centers for Disease Control and Prevention. (2014). National Diabetes Statistics Report.
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002).         Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM         randomised trial. The Lancet, 359(9323), 2072–2077.         http://doi.org/10.1016/S0140-6736(02)08905-5
Chiasson, J.-L., Josse, R. G., Hunt, J. A., Palmason, C., Rodger, N. W., Ross, S. A., ...         Wolever*, T. M. S. (1994). The Efficacy of Acarbose in the Treatment of Patients         with Non–Insulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial. Annals of Internal Medicine, 121(12), 928–935.         http://doi.org/10.7326/0003-4819-121-12-199412150-00004        Crude and Age-Adjusted Rate per 100 of Civilian, Noninstitutionalized Population with         Diagnosed Diabetes, United States, 1980–2011. (2014, September 5). Retrieved         April 24, 2015, from         http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm
Dedonder, R. 1966. Levansucrase from Bacillus subtilis. Methods Enzymol. 8:500–505.
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008). Epidemiology of diabetes         and diabetes-related complications. Physical therapy, 88(11), 1254-1264.
D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, T.J. Orchard, et al.,         Intensive diabetes treatment and cardiovascular disease in patients with type 1         diabetes, N Engl J Med, 353 (2005), pp. 2643–2653
D.R. Whiting, L. Guariguata, C. Weil, J. Shaw, IDF diabetes atlas: global estimates of the         prevalence of diabetes for 2011 and 2030 Diabetes Res Clin Pract, 94 (2011), pp.         311–321
Duncan, A. E. (2012). Hyperglycemia and Perioperative Glucose Management.Current         Pharmaceutical Design, 18(38), 6195–6203.
Edelman, P. S., Maier, H., & Wilhelm, K. (2012). Pramlintide in the Treatment of         Diabetes Mellitus. BioDrugs, 22(6), 375–386. http://doi.org/10.2165/0063030-        200822060-00004
Ferraris, R. P., Yasharpour, S. A. S. A. N., Lloyd, K. C., Mirzayan, R. A. F. F. Y., & Diamond, J. M. (1990). Luminal glucose concentrations in the gut under normal         conditions. American Journal of Physiology-Gastrointestinal and Liver         Physiology, 259(5), G822-G837.
Gay, P., Le Coq, D., Steinmetz, M., Ferrari, E., & Hoch, J. A. (1983). Cloning structural         gene sacB, which codes for exoenzyme levansucrase of Bacillus subtilis:         expression of the gene in Escherichia coli. Journal of bacteriology,153(3), 1424-        1431.
Gray, G. M., & Ingelfinger, F. J. (1966). Intestinal absorption of sucrose in man:         interrelation of hydrolysis and monosaccharide product absorption. Journal of         Clinical Investigation, 45(3), 388.
Grant, R. W., Buse, J. B., & Meigs, J. B. (2005). Quality of Diabetes Care in U.S.         Academic Medical Centers Low rates of medical regimen change. Diabetes Care,         28(2), 337–442. http://doi.org/10.2337/diacare.28.2.337
Grant, R. W., Pirraglia, P. A., Meigs, J. B., & Singer, D. E. (2004). Trends in complexity         of diabetes care in the United States from 1991 to 2000. Archives of Internal         Medicine, 164(10), 1134–1139. http://doi.org/10.1001/archinte.164.10.1134
Halschou, K., Bukhave, K., & Rikardt, J. (2012). Intestinal Disaccharidase Activity and         Uptake of Glucose from Sucrose. In S. Chackrewarthy (Ed.), Glucose Tolerance.         InTech. Retrieved from http://www.intechopen.com/books/glucose-        tolerance/intestinal-disaccharidase-activity-and-uptake-of-glucose-from-sucrose
Hanahan, D. (1983). Studies on transformation of Escherichia coli with plasmids. Journal         of Molecular Biology, 166(4), 557–580.
Hoffmann, J., & Spengler, M. (1997). Efficacy of 24-Week Monotherapy With Acarbose,         Metformin, or Placebo in Dietary-Treated NIDDM Patients: The Essen-II Study.         The American Journal of Medicine, 103(6), 483–490.         http://doi.org/10.1016/S0002-9343(97)00252-0        Intensive blood-glucose control with sulphonylureas or insulin compared with         conventional treatment and risk of complications in patients with type 2 diabetes         (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Jenkins, D. J. A., Wolever, T. M. S., & Jenkins, A. L. (1988). Starchy Foods and         Glycemic Index. Diabetes Care, 11(2), 149–159.         http://doi.org/10.2337/diacare.11.2.149
Jones, M. C. (2007). Therapies for diabetes: pramlintide and exenatide. American Family         Physician, 75(12), 1831–1835.
J Reizer, S. L. S. (1992). Functional interactions between proteins of the         phosphoenolpyruvate:sugar phosphotransferase systems of Bacillus subtilis and         Escherichia coli. The Journal of Biological Chemistry, 267(13), 9158–69.        Jenkins, D. J., Wolever, T. M., & Jenkins, A. L. (1988). Starchy foods and glycemic         index. Diabetes care, 11(2), 149-159.
Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Cotran, Ramzi S. ; Robbins, Stanley L.         (2005). Robbins and Cotran Pathologic Basis of Disease (7th ed.). Philadelphia,         Pa.: Saunders. pp. 1194–1195. ISBN 0-7216-0187-1. Lancet. 1998 Sep 12;         352(9131):837-53.
Kundig, W., Ghosh, S., & Roseman, S. (1964). PHOSPHATE BOUND TO HISTIDINE         IN A PROTEIN AS AN INTERMEDIATE IN A NOVEL PHOSPHO-        TRANSFERASE SYSTEM. Proceedings of the National Academy of Sciences of         the United States of America, 52, 1067–1074.
Lebovitz, H. E. (1997). ALPHA-GLUCOSIDASE INHIBITORS. Endocrinology and         Metabolism Clinics of North America, 26(3), 539–551.         http://doi.org/10.1016/S0889-8529(05)70266-8
Lourens-Hattingh, A., & Viljoen, B. C. (2001). Yogurt as probiotic carrier food.         International Dairy Journal, 11(1–2), 1–17. http://doi.org/10.1016/S0958-        6946(01)00036-X
Malagelada, J. R., Bazzoli, F., Elewaut, A., Fried, M., Krabshuis, J. H., Lindberg, G., ...         Vakil, N. (2007). World Gastroenterology Organisation Practice Guidelines.         Dysphagia. Retrieved from http://almacen-        gpc.dynalias.org/publico/Dysphagia%20WGO%202004%20Ingles.pdf
Man, C. D., Camilleri, M., & Cobelli, C. (2006). A System Model of Oral Glucose         Absorption: Validation on Gold Standard Data. IEEE Transactions on Biomedical         Engineering, 53(12), 2472–2478. http://doi.org/10.1109/TBME.2006.883792
Meigs, J. B., Nathan, D. M., Wilson, P. W., Cupples, L. A., & Singer, D. E. (1998).         Metabolic risk factors worsen continuously across the spectrum of nondiabetic         glucose tolerance. The Framingham Offspring Study. Annals of Internal Medicine,         128(7), 524–533.
Narimasa, S., Tatsuo, H., Mitsutaka, Y., & Toshio, I. (1979). Action of human pancreatic         and salivary α-amylases on maltooligosaccharides: Evaluation of kinetic         parameters. Clinica Chimica Acta, 97(2–3), 253–260.         http://doi.org/10.1016/0009-8981(79)90423-6
National Diabetes Data Group. (1979). Classification and Diagnosis of Diabetes Mellitus         and Other Categories of Glucose Intolerance. Diabetes, 28(12), 1039–1057.         http://doi.org/10.2337/diab.28.12.1039
Nissle, A. (1959). [Explanations of the significance of colonic dysbacteria & the         mechanism of action of E. coli therapy (mutaflor)]. Die Medizinische, 4(21),         1017–1022.
Parkin, C. G., & Brooks, N. (2002). Is postprandial glucose control important? Is it         practical in primary care settings?. Clinical Diabetes, 20(2), 71-76.
Patterson, Joan (2013). Many Schools Cutting Back on Physical Education. Las Vegas         Review - Journal.        Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S.         adults. The Third National Health and Nutrition Examination Survey, 1988-1994.
Peng, C.-K., Buldyrev, S. V., Havlin, S., Simons, M., Stanley, H. E., & Goldberger, A. L.         (1994). Mosaic organization of DNA nucleotides. Physical Review E, 49(2),         1685–1689. http://doi.org/10.1103/PhysRevE.49.1685
Rathmann, W., & Giani, G. (2004). Global Prevalence of Diabetes: Estimates for the         Year 2000 and Projections for 2030: Response to Wild et al. Diabetes Care, 2568-        2569.
Recorbet, G. H. I. S. L. A. I. N. E., Robert, C., Givaudan, A., Kudla, B., Normand, P., & Faurie, G. (1993). Conditional suicide system of Escherichia coli released into         soil that uses the Bacillus subtilis sacB gene. Applied and environmental         microbiology, 59(5), 1361-1366.
Ried, J. L., and A. Collmer. 1987. An nptI-sacB-sacR cartridge for constructing directed,         unmarked mutations in Gram-negative bacteria by marker exchange-eviction         mutagenesis. Gene 57:239–246.
Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007).         Pramlintide Improved Glycemic Control and Reduced Weight in Patients With         Type 2 Diabetes Using Basal Insulin. Diabetes Care, 30(11), 2794–2799.         http://doi.org/10.2337/dc07-0589
Saydah, S. H., Miret, M., Sung, J., Varas, C., Gause, D., & Brancati, F. L. (2001).         Postchallenge Hyperglycemia and Mortality in a National Sample of U.S. Adults.         Diabetes Care, 24(8), 1397–1402. http://doi.org/10.2337/diacare.24.8.1397
Snelling, Anatasia; Korba, Casey; Burkey, Alyvia (2007). The National School Lunch         and Competitive Food Offerings and Purchasing Behaviors of High School         Students, 77(10), 701-705.
Sonnenborn, Ulrich; Schulze, Jurgen. 2009. The Non-Pathogenic Escherichia coli strain         Nissle 1917 - Features of a Versatile Probiotic. Microbial Ecology in Health and         Disease, (21), 122-158.
S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso, Mortality from coronary         heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and         without prior myocardial infarction, N Engl J Med, 339 (1998), pp. 229–234
Schultz, M. (2008). Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.         Inflammatory Bowel Diseases, 14(7), 1012–1018.         http://doi.org/10.1002/ibd.20377
Seifter, S., & Dayton, S. (1950). The estimation of glycogen with the anthrone reagent.         Archives of Biochemistry, 25(1), 191–200.
Shulman, N. B., Martinez, B., Brogan, D., Carr, A. A., & Miles, C. G. (1986). Financial         cost as an obstacle to hypertension therapy. American Journal of Public Health,         76(9), 1105–1108.
Suwattee, P., Lynch, J. C., & Pendergrass, M. L. (2003). Quality of Care for Diabetic         Patients in a Large Urban Public Hospital. Diabetes Care, 26(3), 563–568.         http://doi.org/10.2337/diacare.26.3.563
Temelkova-Kurktschiev, T. S., Koehler, C., Henkel, E., Leonhardt, W., Fuecker, K., & Hanefeld, M. (2000). Postchallenge plasma glucose and glycemic spikes are more         strongly associated with atherosclerosis than fasting glucose or HbA1c level.
Diabetes Care, 23(12), 1830–1834. http://doi.org/10.2337/diacare.23.12.1830        What are normal blood glucose levels? Retrieved from Virginia Mason Medical Center         website: https://www.virginiamason.org/whatarenormalbloodglucoselevels.         Accessed: May. 5th ,2015
TEAM
PROJECT
POLICY AND PRACTICES
ATTRIBUTIONS
CONTACT US
ABOUT
University of Virginia iGEM
148 Gilmer Hall
485 McCormick Road
Charlottesville, Virginia 22904
United States of America
virginia.igem@gmail.com
